Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical
presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; …

In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers
are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical …

For the last two decades, pathogenic concepts in Parkinson disease (PD) have revolved
around the toxicity and spread of α-synuclein. Thus, α-synuclein would follow caudo-rostral …

The aggregation and prion-like propagation of α-synuclein are involved in the pathogenesis
of Parkinson's disease. However, the underlying mechanisms regulating the assembly and …

Non-motor symptoms (NMS) of Parkinson's disease can be predominant as the disease
advances, thereby constituting a major source of disease burden for patients and caregivers …

Olfactory dysfunction is common in Parkinson's disease (PD) and often predates the
diagnosis by years, reflecting early deposition of Lewy pathology, the histologic hallmark of …

Existing therapeutic strategies for managing Parkinson disease (PD), which focus on
addressing the loss of dopamine and dopaminergic function linked with degeneration of …

Dementia with Lewy bodies (DLB) and Parkinson's disease-dementia (PDD), although
sharing many clinical, neurochemical and morphological features, according to DSM-5, are …

Parkinson's Disease (PD) is a highly prevalent neurodegenerative disease among older
adults. PD neuropathology is marked by the progressive loss of the dopaminergic neurons …